Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.

Globus Medical (NYSE:GMED – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Friday. Several other equities analysts ...

HighTower Advisors LLC raised its stake in Globus Medical, Inc. (NYSE:GMED – Free Report) by 2.4% during the fourth quarter, ...

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where Globus Medical, Inc. (NYSE:GMED) stands against ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

In a report released today, Mathew Blackman from Stifel Nicolaus maintained a Buy rating on Globus Medical (GMED – Research Report), with a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

In this article, we are going to take a look at where Globus Medical, Inc. (NYSE:GMED) stands against the other medical technology stocks. The MedTech sector is crucial in healthcare, which ...